Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Shares Outstanding (Weighted Average) (2017 - 2025)

Inmune Bio's Shares Outstanding (Weighted Average) history spans 9 years, with the latest figure at $24.1 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 19.6% year-over-year to $24.1 million; the TTM value through Sep 2025 reached $24.1 million, up 19.6%, while the annual FY2024 figure was $19.9 million, 10.92% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $24.1 million at Inmune Bio, up from $22.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $24.1 million in Q3 2025 and bottomed at $14.3 million in Q1 2021.
  • The 5-year median for Shares Outstanding (Weighted Average) is $17.9 million (2022), against an average of $18.5 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) soared 35.98% in 2021 before it changed 0.0% in 2023.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $16.1 million in 2021, then rose by 11.14% to $17.9 million in 2022, then grew by 0.3% to $18.0 million in 2023, then grew by 10.92% to $19.9 million in 2024, then grew by 21.05% to $24.1 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Shares Outstanding (Weighted Average) are $24.1 million (Q3 2025), $22.9 million (Q2 2025), and $22.5 million (Q1 2025).